Citius Pharmaceuticals Reports First Product Revenue of $1.67M, Narrows Q3 Loss Per Share
CTXR sits 22% above its 52-week low of $0.57.
Summary
Citius Pharmaceuticals reported its Q3 FY2026 results, marking a significant milestone with $1.67 million in product revenue, which began in December 2025. While the company posted a net loss of $(21.23) million, the diluted loss per share of $(0.95) improved from $(1.27) in the prior year. This initiation of product revenue, coupled with early commercial traction, channel expansion, and positive clinical validation, is a crucial development for a company that has previously faced significant financial distress and a going concern warning. Traders will closely watch the continued growth of this new revenue stream and the company's progress towards sustainable profitability.
At the time of this announcement, CTXR was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.57 to $2.48. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.